View Past PerformanceBioasis Technologies 대차대조표 건전성재무 건전성 기준 점검 0/6Bioasis Technologies 의 상태를 파악하기에는 데이터가 부족합니다.핵심 정보n/a부채/자본 비율n/a부채이자보상배율n/a현금n/a자본n/a총부채n/a총자산n/a최근 재무 건전성 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Jan 25Midatech Pharma plc (AIM:MTPH) cancelled the acquisition of Bioasis Technologies Inc. (TSXV:BTI).Midatech Pharma plc (AIM:MTPH) entered into a definitive agreement to acquire Bioasis Technologies Inc. (TSXV:BTI) for $5.5 million on December 13, 2022. As per the terms of the transaction, MTPH shall issue 75,884,553 new ordinary shares at an exchange ratio of 0.9556 Ordinary Shares for every 1 Bioasis Share. A private placement equity financing of approximately $10 million that will be completed concurrently with Midatech’s acquisition of Bioasis. Upon completion of the Arrangement and the Midatech Financing, it is expected that the current Midatech securityholders, the current Bioasis securityholders and the Midatech Financing investor will own approximately 39.8%, 30.7% and 9.9% stake, respectively. The combination of Bioasis and Midatech will create a multi-asset rare and orphan disease company that will be renamed Biodexa Pharmaceuticals PLC (“Biodexa”). Post deal completion, Stephen Parker shall serve as non-executive chairman, Deborah Rathjen (currently Bioasis’ executive chair and Chief Executive Officer), Mario Saltarelli (currently a Bioasis director) and Simon Turton shall serve as non-executive directors and Stephen Stamp shall serve as Chief Executive Officer and director. Bioasis and Midatech shall pay a termination of $330,000 to the other party. Completion of the Arrangement is subject to the completion of the Midatech Financing and Midatech shareholder approval along with other closing conditions customary for transaction of this nature including, among other things, approval of the Arrangement by the Supreme Court of British Columbia, the TSX-V having approved the de-listing of the Bioasis Shares, Bioasis Shareholders shall not have exercised Dissent Rights in connection with the Arrangement with respect to more than 10% of the issued and outstanding Bioasis Shares and the approval of at least two-thirds of the votes cast by all Bioasis shareholders. The board of directors of Bioasis (the “Board”) has unanimously approved the Arrangement Agreement and resolved to recommend that Bioasis securityholders vote in favour of the Arrangement at the Bioasis Meeting. As of December 19, 2022, Midatech is no longer required to seek delisting from AIM following completion of the arrangement. The transaction is expected to close in the first quarter of 2023. The transaction is expected to close by the end of February 2023. The Arrangement is anticipated to be completed on or about February 8, 2023. Evans & Evans, Inc. acted as fairness opinion provider to Bioasis. Goodmans LLP and Lawson Lundell LLP are Bioasis’ Canadian legal advisors. Ladenburg Thalmann & Co. Inc. (“Ladenburg”) is Bioasis’ financial advisor. Pursuant to the terms of Ladenburg’s engagement by Bioasis, Ladenburg is entitled to receive a fee upon the completion of the Arrangement in the form of Midatech securities. Ladenburg Thalmann & Co. Inc. is acting as the exclusive placement agent for Midatech. James Dance, Matthew Chandler and Rob Patrick of Strand Hanson Limited acted as financial advisors to Midatech. Andrew Thacker and James Pope of Turner Pope Investments (TPI) Ltd acted as brokers and The Bank of New York Mellon acted as depository bank and Neville Registrars Limited acted as transfer agent for Midatech. Brown Rudnick LLP, Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. and Fasken Martineau DuMoulin LLP all acted as legal advisors while Mazars LLP acted as accountant to Midatech. Midatech Pharma plc (AIM:MTPH) cancelled the acquisition of Bioasis Technologies Inc. (TSXV:BTI) on January 23, 2023. One of the conditions precedent to completion of the Arrangement was approval of the Arrangement and a number of related matters by the Midatech shareholders. Midatech has announced that its shareholders did not approve the Arrangement at the general meeting of Midatech shareholders held on January 23, 2023.공시 • Dec 22Bioasis Technologies Inc., Annual General Meeting, Feb 03, 2023Bioasis Technologies Inc., Annual General Meeting, Feb 03, 2023.재무 상태 분석단기부채: BIOA.F 의 단기 자산이 단기 부채를 감당하는지 판단하기에는 데이터가 부족합니다.장기 부채: BIOA.F의 단기 자산이 장기 부채를 충당하는지 판단하기에 데이터가 부족합니다.부채/자본 비율 추이 및 분석부채 수준: satisfactory인지 판단하기 위해 BIOA.F 의 순 부채 대 자기자본 비율을 계산하기에는 데이터가 부족합니다.부채 감소: 지난 5년 동안 BIOA.F의 부채 대비 자본 비율이 감소했는지 판단하기에 데이터가 부족합니다.부채 범위: BIOA.F 의 부채가 영업 현금 흐름에 의해 잘 충당되었는지 판단하기에는 데이터가 부족합니다.이자 보장: BIOA.F 의 부채에 대한 이자 지급이 EBIT에 의해 잘 충당되었는지 판단할 데이터가 부족합니다.대차대조표건전한 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 건실한 기업.View Dividend기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/21 19:44종가2026/04/13 00:00수익2022/11/30연간 수익2022/02/28데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Bioasis Technologies Inc.는 3명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Nathaniel CallowayEdison Investment ResearchWilliam GregozeskiGreenridge Global LLCJohn VandermostenZacks Small-Cap Research
공시 • Jan 25Midatech Pharma plc (AIM:MTPH) cancelled the acquisition of Bioasis Technologies Inc. (TSXV:BTI).Midatech Pharma plc (AIM:MTPH) entered into a definitive agreement to acquire Bioasis Technologies Inc. (TSXV:BTI) for $5.5 million on December 13, 2022. As per the terms of the transaction, MTPH shall issue 75,884,553 new ordinary shares at an exchange ratio of 0.9556 Ordinary Shares for every 1 Bioasis Share. A private placement equity financing of approximately $10 million that will be completed concurrently with Midatech’s acquisition of Bioasis. Upon completion of the Arrangement and the Midatech Financing, it is expected that the current Midatech securityholders, the current Bioasis securityholders and the Midatech Financing investor will own approximately 39.8%, 30.7% and 9.9% stake, respectively. The combination of Bioasis and Midatech will create a multi-asset rare and orphan disease company that will be renamed Biodexa Pharmaceuticals PLC (“Biodexa”). Post deal completion, Stephen Parker shall serve as non-executive chairman, Deborah Rathjen (currently Bioasis’ executive chair and Chief Executive Officer), Mario Saltarelli (currently a Bioasis director) and Simon Turton shall serve as non-executive directors and Stephen Stamp shall serve as Chief Executive Officer and director. Bioasis and Midatech shall pay a termination of $330,000 to the other party. Completion of the Arrangement is subject to the completion of the Midatech Financing and Midatech shareholder approval along with other closing conditions customary for transaction of this nature including, among other things, approval of the Arrangement by the Supreme Court of British Columbia, the TSX-V having approved the de-listing of the Bioasis Shares, Bioasis Shareholders shall not have exercised Dissent Rights in connection with the Arrangement with respect to more than 10% of the issued and outstanding Bioasis Shares and the approval of at least two-thirds of the votes cast by all Bioasis shareholders. The board of directors of Bioasis (the “Board”) has unanimously approved the Arrangement Agreement and resolved to recommend that Bioasis securityholders vote in favour of the Arrangement at the Bioasis Meeting. As of December 19, 2022, Midatech is no longer required to seek delisting from AIM following completion of the arrangement. The transaction is expected to close in the first quarter of 2023. The transaction is expected to close by the end of February 2023. The Arrangement is anticipated to be completed on or about February 8, 2023. Evans & Evans, Inc. acted as fairness opinion provider to Bioasis. Goodmans LLP and Lawson Lundell LLP are Bioasis’ Canadian legal advisors. Ladenburg Thalmann & Co. Inc. (“Ladenburg”) is Bioasis’ financial advisor. Pursuant to the terms of Ladenburg’s engagement by Bioasis, Ladenburg is entitled to receive a fee upon the completion of the Arrangement in the form of Midatech securities. Ladenburg Thalmann & Co. Inc. is acting as the exclusive placement agent for Midatech. James Dance, Matthew Chandler and Rob Patrick of Strand Hanson Limited acted as financial advisors to Midatech. Andrew Thacker and James Pope of Turner Pope Investments (TPI) Ltd acted as brokers and The Bank of New York Mellon acted as depository bank and Neville Registrars Limited acted as transfer agent for Midatech. Brown Rudnick LLP, Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. and Fasken Martineau DuMoulin LLP all acted as legal advisors while Mazars LLP acted as accountant to Midatech. Midatech Pharma plc (AIM:MTPH) cancelled the acquisition of Bioasis Technologies Inc. (TSXV:BTI) on January 23, 2023. One of the conditions precedent to completion of the Arrangement was approval of the Arrangement and a number of related matters by the Midatech shareholders. Midatech has announced that its shareholders did not approve the Arrangement at the general meeting of Midatech shareholders held on January 23, 2023.
공시 • Dec 22Bioasis Technologies Inc., Annual General Meeting, Feb 03, 2023Bioasis Technologies Inc., Annual General Meeting, Feb 03, 2023.